Menopause

Arimidex receives FDA priority review for early breast cancer indication

Published in Women's Health Weekly, June 27th, 2002

The U.S. Food and Drug Administration has granted a 6-month priority review status to the AstraZeneca (AZN) supplemental new drug application (sNDA), which provides data for the use of Arimidex (anastrozole) tablets in the adjuvant treatment of early breast cancer in postmenopausal women.

AstraZeneca filed the sNDA with the FDA for Arimidex on March 4, 2002, having received fast track designation in December of 2001, allowing a rolling submission. Priority review status is granted for new drugs or indications that represent a significant improvement in efficacy or safety over existing treatments.

"AstraZeneca is committed to constantly expanding the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-06-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry